Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

19.01USD
14 Dec 2017
Change (% chg)

$-0.31 (-1.60%)
Prev Close
$19.32
Open
$19.39
Day's High
$19.58
Day's Low
$18.88
Volume
108,317
Avg. Vol
245,028
52-wk High
$27.07
52-wk Low
$8.73

Chart for

About

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria... (more)

Overall

Beta: 3.56
Market Cap(Mil.): $912.55
Shares Outstanding(Mil.): 48.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Omeros Corporation Announces Fda Approval Of Omidria For Use In Pediatric Patients

* OMEROS CORPORATION ANNOUNCES FDA APPROVAL OF OMIDRIA® FOR USE IN PEDIATRIC PATIENTS

Dec 12 2017

BRIEF-Omeros Corp reports Q3 loss per share $0.16

* Omeros Corporation reports third quarter 2017 financial results

Nov 09 2017

BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721

* OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

Oct 26 2017

BRIEF-Omeros Corp amends term loan agreement

* On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016​

Oct 17 2017

BRIEF-OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

* OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

Oct 05 2017

BRIEF-Omeros announces pricing of public offering of common stock

* Omeros announces pricing of public offering of common stock

Aug 15 2017

BRIEF-Omeros announces public offering of common stock

* Says offering 3.00 million common shares Source text for Eikon: Further company coverage:

Aug 14 2017

BRIEF-Omeros Corporation Q2 loss per share $0.33

* Omeros corporation reports second quarter 2017 financial results

Aug 08 2017

BRIEF-FDA grants orphan drug designation to Omeros’ OMS721

* FDA grants Orphan Drug Designation to Omeros’ OMS721 for treatment of IGA Nephropathy

Aug 04 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.08 +0.43
Novartis AG (NOVN.S) CHF83.85 --
Pfizer Inc. (PFE.N) $36.46 -0.18
Roche Holding Ltd. (ROG.S) CHF241.70 0.00
Roche Holding Ltd. (RO.S) CHF242.50 -0.70
Merck & Co., Inc. (MRK.N) $56.01 -0.90
Bayer AG (BAYGn.DE) €106.50 +1.40
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.77 -0.89
Eli Lilly and Co (LLY.N) $86.50 -1.39

Earnings vs. Estimates